Skip to main content
MedPathMedPath Home
Clinical Trials/2024-511493-67-00
2024-511493-67-00
Recruiting
Phase 1

A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts1 site in 1 country45 target enrollmentStarted: June 6, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Status
Recruiting
Sponsor
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Enrollment
45
Locations
1
OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

No summary available.

Eligibility Criteria

Ages
18 years to 64 years (18-64 Years)
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Sponsor Class
Laboratory/Research/Testing facility
Responsible Party
Principal Investigator
Principal Investigator

Scientific Trial Coordination

Scientific

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia
2023-510021-16-00Affimed GmbH60
Recruiting
Phase 1
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours
2023-508126-95-00Karolinska University Hospital30
Completed
Phase 1
A first-in-human phase 1, single center, randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of three dose levels of the OVX033 vaccine, after intramuscular administration in healthy subjects aged 18-49 years
2023-506396-94-00Osivax48
Recruiting
Phase 1
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
2022-502867-39-00Amgen Inc.58
Not yet recruiting
Phase 1
Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors
2023-508808-38-00CDR-Life AG49